• Nutritional-GICompleted with Results

  RESULT: Study of liprotamase non-porcine enzymes , protocol number Anthera AN-EPI3333

  This study evaluated the effectiveness of liprotamase, a non-pig-derived pancreatic enzyme replacement therapy (PERT), as compared to Pancreaze®, a pig-derived PERT.

  • Age:

    7 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    17

  • Length of Participation:

    30 weeks

• Nutritional-GICompleted with Results

  SIMPLICITY: Phase 3 study of liprotamase in people with CF-related pancreatic insufficiency , protocol number Anthera AN-EPI3332

  This study evaluated the safety and effectiveness of a new, water-soluble formulation of liprotamase.

  • Age:

    28 Days to 17 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    7

  • Length of Participation:

    24 weeks

• Nutritional-GICompleted with Results

  SOLUTION: Study of Liprotamase in people with CF , protocol number Anthera AN-EPI3331

  This study evaluated the safety and effectiveness of the drug liprotamase in people with CF who were taking digestive enzymes.

  • Age:

    7 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    30% or greater

  • Number of Visits:

    10

  • Length of Participation:

    28 weeks

• Nutritional-GICompleted with Results

  DIGEST S: ALTU-135 for the treatment of CF-related exocrine pancreatic insufficiency , protocol number Alnara Altus 767

  Researchers evaluated people with CF taking liprotamase (ALTU-135), an oral enzyme replacement therapy, for safety concerns during a period of one year.

  • Age:

    7 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    9

  • Length of Participation:

    12 months

• Nutritional-GICompleted with Results

  DIGEST E: Efficacy and safety of ALTU-135 in patients with CF-related exocrine pancreatic insufficiency , protocol number Alnara Altus 726

  This study evaluated the efficacy and safety of liprotamase (a new experimental non-porcine pancreatic enzyme replacement therapy).

  • Age:

    7 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    9

  • Length of Participation:

    10 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.